We are live on
!
Find out more
NCM
Nantahala Capital Management Portfolio holdings
AUM
$1.6B
1-Year Est. Return
121.58%
This Fund
S&P 500
1 Year Est. Return
+121.58%
AUM
$1.6B
AUM Growth
-$75.4M
(-4.5%)
Holding
158
Top Buys
| 1 | +$29.6M | |
| 2 | +$22.9M | |
| 3 | +$22.7M | |
| 4 |
Verastem
VSTM
|
+$19.3M |
| 5 |
The Bancorp
TBBK
|
+$18.5M |
Top Sells
| 1 | +$32.3M | |
| 2 | +$30.5M | |
| 3 | +$30.2M | |
| 4 |
RAPT
RAPT Therapeutics
RAPT
|
+$25.5M |
| 5 |
Globus Medical
GMED
|
+$19.6M |
Sector Composition
| 1 | Healthcare | 61.03% |
| 2 | Consumer Discretionary | 16.41% |
| 3 | Financials | 6.64% |
| 4 | Communication Services | 4.74% |
| 5 | Industrials | 2.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Surrozen
SRZN
$249M
| – | – |
-229,527
|
|
||
|
SSKN
152
DELISTED
Strata Skin Sciences
SSKN
| – | – |
-403,917
|
|
||
153
Align Technology
ALGN
$12.5B
| – | – |
0
|
|
||
154
Teva Pharmaceuticals
TEVA
$38.5B
| – | – |
0
|
|
||
155
Viatris
VTRS
$18.6B
| – | – |
0
|
|
||
156
State Street SPDR S&P Biotech ETF
XBI
$7.79B
| – | – |
0
|
|
||
|
ANEB
157
DELISTED
Anebulo Pharmaceuticals
ANEB
| – | – |
-3,036,325
|
|